

## ASX ANNOUNCEMENT

10 February 2025

# Investor webinar invitation

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to invite shareholders to attend an investor webinar presentation to be held:

**Time:** 10am AWST / 1pm AEDT

**Date:** Tuesday 11th February 2025



The presentation will be delivered by CEO Paul Long and provide an overview of the Company's December quarterly results, with the Company reporting \$9.5m in revenue (unaudited) for the quarter, a record sales month of \$3.6m in December, and the Company's revenue financial year to date already surpassing last year's full year revenue.

In addition, Mr Long will provide an update on LGP's operational activities, including the Company's continued expansion into lucrative European and UK markets and recent acquisition of Australian medicinal cannabis distribution business, Health House.

The webinar will be held via Zoom and will provide attendees the opportunity to submit questions via a moderated Q&A session following the formal presentation.

To register for the webinar, please visit:

[https://us02web.zoom.us/webinar/register/WN\\_ns9G1qVHS2u2E8yzxeN3tA](https://us02web.zoom.us/webinar/register/WN_ns9G1qVHS2u2E8yzxeN3tA)

A recorded copy of the webinar will be made available on Little Green Pharma's website following the event.



**ENDS  
APPROVED FOR RELEASE**



**Alistair Warren**  
Company Secretary



For further information please contact:

**Alistair Warren**  
**Company Secretary**  
Little Green Pharma  
E: [a.warren@lgp.global](mailto:a.warren@lgp.global)  
T: +61 8 6280 0050

**David Tasker**  
**Managing Director**  
Chapter One Advisors  
E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)  
T: +61 433 112 936

## About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has three global production sites for the manufacture of its own-branded and white-label ranges of medicinal cannabis and psychedelic products, being a Danish glasshouse facility, a West Australian indoor craft production facility with a combined nameplate capacity of 30 tonnes of cannabis biomass per annum, and a combined psychedelics clinic, head office and therapeutic goods manufacturing facility located in Western Australia. The Company also owns an Australian medicinal cannabis distribution business.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)

## LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world.

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>

Access past Cannabis Wraps here:

<https://www.investlittlegreenpharma.com/site/investor-centre/cannabis-industry-wrap>